The most recent CDC report estimates an asthma prevalence of 7.9% in the U.S. Although patients with severe asthma make up only 3-10% of the total asthma population, they account for a substantial proportion of asthma morbidity and health expenditures. With the emergence of new biologic therapies targeting cytokines involved in pathogenesis of asthma, severe asthma is no longer considered the “refractory” disease of yesteryear. This session offers guidance on distinguishing characteristics pertinent to individualizing asthma treatment, such as subtype, phenotype, and endotype as well as biomarkers and other measures of assessment that identify patients with severe eosinophilic asthma. Using expert guidelines, the faculty will discuss how to apply these individual factors to treatment management and alleviate the burden of asthma in your practice.
- Recognize the unmet need in current management of severe asthma and the burdens it imparts on patients in your practice
- Identify distinct asthma subtypes, phenotypes, and endotypes
- Identify patients with severe eosinophilic asthma through biomarkers and other measures of assessment
- Select asthma pharmacology with regard to patient subtype, phenotype, or endotype
Session supported by GSK